Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.56 USD
Change Today -0.73 / -8.81%
Volume 58.1K
CLCD On Other Exchanges
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

colucid pharmaceuticals inc (CLCD) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/3/15 - $9.46
52 Week Low
08/4/15 - $7.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

colucid pharmaceuticals inc (CLCD) Related Businessweek News

No Related Businessweek News Found

colucid pharmaceuticals inc (CLCD) Details

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecule for the acute treatment of migraine headaches. Its lead product candidate is Lasmiditan, an oral tablet that is in a Phase III clinical program for the acute treatment of migraine headaches in adults. The company also develops IV lasmiditan, which is Phase II clinical trial for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. CoLucid Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Burlington, Massachusetts.

5 Employees
Last Reported Date: 05/6/15
Founded in 2005

colucid pharmaceuticals inc (CLCD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $271.7K
Vice President of Business Development
Total Annual Compensation: $120.0K
Vice President of Research & Development
Total Annual Compensation: $221.9K
Vice President of Clinical & Regulatory Opera...
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.

colucid pharmaceuticals inc (CLCD) Key Developments

CoLucid Pharmaceuticals, Inc. Appoints Marvin L. White to its Board of Directors and as Chairman of the Audit Committee

CoLucid Pharmaceuticals, Inc. announced the appointment of Marvin L. White to its Board of Directors and as Chairman of the Audit Committee. Mr. White serves as the president and chief executive officer of The MLW Advisory Group, LLC. From 2008 to 2014, Mr. White served as system vice president and chief financial officer of St. Vincent Health, and was responsible for finance, accounting, patient financial services and managed care for 19 hospitals and 36 joint ventures.

CoLucid Pharmaceuticals, Inc.(NasdaqGM:CLCD) added to NASDAQ Composite Index

CoLucid Pharmaceuticals, Inc. has been added to Nasdaq Composite Index.

CoLucid Pharmaceuticals Announces Initiation of First Phase 3 Pivotal Trial of Lasmiditan in Migraine

CoLucid Pharmaceuticals, Inc. announced that the first patient has been randomized in its SAMURAI study, the company's first Phase 3 pivotal trial of lasmiditan. The objective of SAMURAI is to evaluate the safety and efficacy of lasmiditan (100 mg and 200 mg) in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is primary endpoint, and on freedom from the most bothersome associated symptom of migraine (nausea, phonophobia or photophobia), which is secondary endpoint. SAMURAI is a randomized, double-blind, placebo-controlled parallel group study. The study is expected to treat up to 1,483 migraine patients with lasmiditan at approximately 70 U.S. sites for approximately 12 months. SAMURAI is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLCD:US $7.56 USD -0.73

CLCD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLCD.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLCD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUCID PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at